Xiang Hang, Chen Haixu, Li Fan, Liu Jing, Su Yuehan, Hao Lu, Wang Fei, Wang Zheng, Zeng Qiang
Health Management Institute of Chinese PLA General Hospital, Beijing, China.
Beijing Key Laboratory of Normal Aging and Geriatrics, Geriatrics Institute of Chinese PLA General Hospital, Beijing, China.
Cytotherapy. 2015 Nov;17(11):1638-45. doi: 10.1016/j.jcyt.2015.07.006. Epub 2015 Aug 28.
Autologous hematopoietic stem cell transplantation (auto-HSCT) followed by immunoablation is a promising therapy for type 1 diabetes mellitus (T1DM) treatment due to the immunosuppression and immunomodulation mechanisms. Indeed, a considerable number of patients have been able to discontinue insulin use with this treatment. However, nonresponse and relapse occur after auto-HSCT. It is important to select the patients who can potentially benefit from this treatment, but the factors that might influence the therapeutic outcome are unclear. The objective of this study was to explore the predictors for prolonged remission after auto-HSCT therapy.
The data for this study were extracted from an open-label prospective study, which was performed to treat new-onset T1DM patients with auto-HSCT. The 128 patients were categorized into insulin-free (IF) or insulin-dependent (ID) groups according to their response to treatment during the follow-up. We compared the baseline data of the two groups and explored possible prognostic factors and their odd ratios (ORs) with univariate analysis and multivariate logistic regression. Receiver operating characteristic curves (ROC) were performed to test the model discrimination function.
During a follow-up of 28.5 ± 8.3 months, 71 of 128 patients in the IF group discontinued insulin use, whereas 57 of 128 patients in the ID group did not decrease their insulin dose or resumed insulin treatment after a transient remission. Multivariate logistic regression analysis demonstrated that prolonged remission was positively correlated with fasting C-peptide level (OR = 2.60, 95% confidence interval [CI]: 1.16-5.85) but negatively correlated with onset age (OR = 0.36, 95% CI: 0.14-0.88) and tumor necrosis factor-α levels (OR = 0.32, 95% CI: 0.14-0.73). ROC analysis confirmed the combined predictive function of these three variables (AUC = 0.739, 95% CI: 0.655-0.824).
Age and fasting C-peptide and tumor necrosis factor-α levels were identified as possible predictors for prolonged remission following auto-HSCT therapy.
自体造血干细胞移植(auto-HSCT)联合免疫清除疗法因具有免疫抑制和免疫调节机制,是一种很有前景的1型糖尿病(T1DM)治疗方法。实际上,相当一部分患者通过这种治疗能够停用胰岛素。然而,auto-HSCT治疗后会出现无反应和复发情况。选择可能从该治疗中获益的患者很重要,但可能影响治疗结果的因素尚不清楚。本研究的目的是探索auto-HSCT治疗后长期缓解的预测因素。
本研究数据来自一项开放标签的前瞻性研究,该研究旨在用auto-HSCT治疗新诊断的T1DM患者。128例患者根据随访期间对治疗的反应分为无胰岛素组(IF)或胰岛素依赖组(ID)。我们比较了两组的基线数据,并通过单因素分析和多因素逻辑回归探索可能的预后因素及其比值比(OR)。绘制受试者工作特征曲线(ROC)以检验模型判别功能。
在28.5±8.3个月的随访期间,IF组128例患者中有71例停用胰岛素,而ID组128例患者中有57例未减少胰岛素剂量或在短暂缓解后恢复胰岛素治疗。多因素逻辑回归分析表明,长期缓解与空腹C肽水平呈正相关(OR = 2.60,95%置信区间[CI]:1.16 - 5.85),但与发病年龄呈负相关(OR = 0.36,95%CI:0.14 - 0.88)以及与肿瘤坏死因子-α水平呈负相关(OR = 0.32,95%CI:0.14 - 0.73)。ROC分析证实了这三个变量的联合预测功能(AUC = 0.739,95%CI:0.655 - 0.824)。
年龄、空腹C肽和肿瘤坏死因子-α水平被确定为auto-HSCT治疗后长期缓解的可能预测因素。